Cost considerations for clinicians prescribing biologic drugs: Who pays? - 05/08/20
Doi : 10.1016/j.jaci.2020.03.033
Christopher Hvisdas, PharmD a, Patrick K. Gleeson, MD b, Andrea J. Apter, MD, MSc, MA b, ⁎ 
a Ambulatory Care Department of Pharmacy, Penn Presbyterian Medical Center, University of Pennsylvania, Philadelphia, Pa
b Section of Allergy & Immunology, Division of Pulmonary, Allergy, & Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa
∗Corresponding author: Andrea J. Apter, MD, MSc, MA, 829 Gates Bldg, Hospital of the University of Pennsylvania, 3600 Spruce St, Philadelphia, PA 19104.829 Gates BldgHospital of the University of Pennsylvania3600 Spruce StPhiladelphiaPA19104
Key words : Asthma, pharmacy benefit manager, specialty pharmacy, specialty drugs, biologic drugs
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
© 2020
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 146 - N° 2
P. 266-269 - août 2020 Retour au numéro
Article précédent
- Gene therapy for Wiskott-Aldrich syndrome: History, new vectors, future directions
- Francesca Ferrua, Francesco Marangoni, Alessandro Aiuti, Maria Grazia Roncarolo
- Targeting maternal immune function during pregnancy for asthma prevention in offspring: Harnessing the “farm effect”?
- Patrick G. Holt, Deborah H. Strickland, Adnan Custovic
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?